Edition:
United Kingdom

Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

21.53USD
24 May 2019
Change (% chg)

$0.28 (+1.32%)
Prev Close
$21.25
Open
$21.78
Day's High
$21.79
Day's Low
$21.53
Volume
2,947
Avg. Vol
3,307
52-wk High
$22.17
52-wk Low
$11.30

Summary

Name Age Since Current Position

Alf Nicklasson

64 2015 Independent Chairman of the Board

Emmanuel Dulac

49 2019 Chief Executive Officer

Kirsten Drejer

63 2019 Independent Vice Chairman of the Board

Ivan Moeller

47 2018 Senior Vice President, Technical Development & Operations

Andrew Parker

54 2017 Executive Vice President, Chief Scientific Officer

Adam Steensberg

45 2019 Executive Vice President, Chief Medical and Development Officer (CMDO)

Marino Garcia

53 2018 Senior Vice President, Corporate and Business Development

Hanne Heidenheim Bak

66 2016 Director, Employee Representative

Jens Stenvang

65 2014 Director, Employee Representative

Jeffrey Berkowitz

52 2019 Independent Director

Bernadette Connaughton

2019 Independent Director

Leonard Kruimer

61 2019 Independent Director

Alain Munoz

70 2007 Independent Director

Michael Owen

68 2012 Independent Director

Biographies

Name Description

Alf Nicklasson

Dr. Alf Gunnar Martin (Martin) Nicklasson, Ph.D. has been Independent Chairman of the Board at Zealand Pharma A/S since April 21, 2015. Martin has held broad-based executive experience from positions in European pharmaceutical and biotech companies. He held executive vice president positions at AstraZeneca PLC and has served as President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB. Prior to this, he held a number of leadership positions at AB Astra and Kabi Pharmacia AB. Martin Nicklasson is chairman of the board of Orexo AB and Kymab Ltd., as well as Board Member of Basilea Pharmaceutica Ltd. He is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from the Uppsala University, where he is Associate Professor at the Department of Pharmaceutics.

Emmanuel Dulac

Dr. Emmanuel Dulac has been appointed Chief Executive Officer of ZEALAND PHARMA A/S effective as of April 22, 2019. He has 25 years of experience in the pharmaceutical industry, with a strong record of commercial and operational leadership underpinned by several senior roles in Europe and North America. Since August 2016, Emmanuel has been the Chief Commercial Officer at Alnylam Pharmaceuticals. He previously held leadership positions at Novartis, Abbott, Sanofi, and Shire.

Kirsten Drejer

Dr. Kirsten Aarup Drejer has been Independent Vice Chairman of the Board at ZEALAND PHARMA A/S since April 4, 2019. She has been Independent Director of the Company since April 19, 2018. She holds PhD in Pharmacology and a MSc in Pharmacy from the University of Copenhagen. Kirsten Drejer is co-founder and previous CEO of Symphogen A/S (2000-2016) which is a privately biotech company dedicated to the development of mAb mixtures to provide effective treatments to serious diseases including with oncology. Dr. Drejer holds more than 30 years of international experience in the pharmaceutical and biotech industry. Before co-founding Symphogen A/S in 2000, Kirsten Drejer held several scientific and managerial positions at Novo Nordisk A/S, including four years as Director of Diabetes Discovery, and three years as Corporate Facilitator. She is Chairman of the board of Antag Therapeutics, Bioneer and Resother Pharma, and Board member of Bioporto, Lyhne & Co.

Ivan Moeller

Mr. Ivan Moeller has been appointed Senior Vice President, Technical Development & Operations at ZEALAND PHARMA A/S, effective as of March 1, 2018. He brings experience from numerous senior management positions in the international pharmaceutical industry, including roles at Novartis in both generics and pharmaceutical manufacturing, as well as strategy, quality assurance, contract manufacturing and supply chain leadership in Germany, the U.S. and Switzerland. Prior to joining Novartis, Ivan Moeller was project leader at The Boston Consulting Group in New York, NY where he led client engagements in the pharmaceutical R&D and manufacturing areas. He started his career at PolyPeptide Laboratories where he was Head of Production site. He holds a Master of Science in Chemical Engineering from the Technical University of Denmark (DTU) and a Master of Business Administration from Harvard Business School.

Andrew Parker

Mr. Andrew Parker has been Executive Vice President and Chief Scientific Officer of Zealand Pharma A/S since 2017. He has previously been Senior Vice President and Chief Scientific Officer since July 1, 2016. He comes from a position as General Partner and Scientific Director for the Life Sciences Investment Fund Eclosion2 & Cie SCPC in Switzerland. In parallel, he has held the position as CEO for Arisgen SA (an Eclosion2 portfolio company developing an oral peptide drug delivery technology). Andrew has more than twenty years of experience from senior leadership and managerial positions in international pharmaceutical, biotech and start-up companies, including several years with Shire Pharmaceuticals, Opsona Therapeutics, and AstraZeneca to mention a few. He holds a Ph.D. from the National Institute for Medical Research at Mill Hill, London, conducted post-doctoral research at Johns Hopkins Medical School, Baltimore, USA, and also has an MBA from the University of Warwick Business School, UK. Andrew has published more than 25 scientific articles in international journals.

Adam Steensberg

Mr. Adam Steensberg, M.D. has been Executive Vice President, Chief Medical and Development Officer (CMDO) at Zealand Pharma A/S since 2017. He no longer serves as Interim Chief Executive Officer of the Company effective as of April 22, 2019. He has held the position since March 1, 2019. He has previously been Senior Vice President and Chief Medical and Development Officer at Zealand Pharma A/S since March 19, 2015. Mr. Adam Steensberg joined Zealand in 2010 as Head of Clinical Development. Since 2011 he has been leading all development activities. Prior to joining Zealand, Adam has led several clinical research teams as medical director at Novo Nordisk A/S, and he has experience as clinician from the University hospital of Copenhagen. He has served as medical and scientific advisor within endocrinology, cardiology, gastroenterology, and rheumatology. He has experience with leading regulatory strategies and has been instrumental in implementing a patient-centric discovery and development process at Zealand. Adam has published more than 45 peer-reviewed scientific papers in international journals. Adam holds a Medical Doctor degree followed by a Doctor of Medical Sciences (DMSc/ dr.med) from the University of Copenhagen, Denmark and an MBA from IMD, Switzerland.

Marino Garcia

Mr. Marino Garcia is Senior Vice President, Corporate and Business Development of the Company. Marino holds a Bachelor’s Degree in Business Administration from Concordia University in Montreal, Quebec, and an MBA from the Richard Ivey School of Business at Western University in London, Ontario. Prior to joining Zealand, Marino was instrumental in leading business development and corporate strategy at Synergy Pharmaceuticals Inc. Marino has more than 20 years of global experience in commercial, operational, corporate strategy, and business development. He has held various U.S. and international leadership roles of increasing responsibility at pharmaceutical companies, including Aptalis Pharma, Aspreva Pharmaceuticals, Eli Lilly & Co, Schering Plough, and Pfizer.

Hanne Heidenheim Bak

Ms. Hanne Heidenheim Bak has been appointed Director, Employee Representative at Zealand Pharma A/S, effective as of April 19, 2016. She previously held that position at the Company from April 17, 2012 to April 29, 2014. She is Senior Project Director, GI, External Relations and Collaborations and she holds M.Sc. (Pharm) from the Danish University of Pharmaceutical Sciences. Prior to joining Zealand in 2006, Hanne H. Bak worked 8 years as Project Manager of late-phase development programs at H. Lundbeck A/S, followed by 9 years as Executive Director at the Lundbeck Institute.

Jens Stenvang

Mr. Jens Peter Stenvang has been appointed Employee Representative on the Board of Directors of Zealand Pharma A/S, effective as of April 29, 2014. He holds a degree as laboratory technician in Biology. He has worked with cancer and diabetes research at universities including UC-Berkeley, California. Before joining Zealand in October 2010, Jens Peter worked for DAKO and Beckman Coulter as global Flow Cytometry support. Jens Peter has been member of the board of Dansk Selskab for Flowcytometri since 1990, excluding a short break from 2010-2012.

Jeffrey Berkowitz

Mr. Jeffrey Berkowitz, JD, has been Independent Member of the Board of ZEALAND PHARMA A/S since April 4, 2019. He has been global executive with extensive branded and generic pharmaceutical, retail pharmacy, wholesale drug distribution, specialty, and healthcare services. He has leadership experience in P&L accountable roles. He is a member of the Board of Directors of H. Lundbeck A/S, Esperion Theraptics, Inc. and Infinity Pharmaceuticals, Inc.

Bernadette Connaughton

Ms. Bernadette M. Connaughton has been Independent Member of the Board of ZEALAND PHARMA A/S since April 4, 2019. She has more than 30 years of global strategic, commercial and leadership expertise, and a broad perspective on the strategy, capabilities and governance required for successful execution in U.S. and international markets.

Leonard Kruimer

Mr. Leonard Kruimer has been Independent Member of the Board of ZEALAND PHARMA A/S since April 4, 2019. He has more than 30 years of experience in corporate finance, planning and strategy, including 15 years in senior executive positions in private and publicly listed biotechnology companies.

Alain Munoz

Dr. Alain Munoz, Ph.D. has been Independent Member of the Board of Directors at Zealand Pharma A/S since 2007. He served as Director of the Company from 2005 until 2006 when he resigned. Alain Munoz has over 20 years of experience in the pharmaceutical industry at senior management level. Within the Sanofi Group he served as SVP for International development and in Fournier Laboratories as SVP for the Pharmaceutical division. He is Independant Board member of Valneva SEHybrigenics, , Auris medical and Oxthera, as well as adviser to Kurma Biofund. Alain Munoz holds an MD in Cardiology and Anaesthesiology from the Hospital Pitie-Salpetriere, Paris. He has numerous publications and has been a member of the scientific committee of the French Drug Agency (ANSM).

Michael Owen

Dr. Michael John Owen has been Independent Director at Zealand Pharma A/S since 2012. Michael J. Owen is co-founder and was CSO at Kymab Ltd. (UK). Before joining Kymab, he had several leading positions at GlaxoSmithKline, latterly as SVP and head of biopharmaceuticals research. Prior to joining GSK in 2001, he headed the Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He has more than 20 years of research experience with a focus on the immune system. He has more than 150 publications and membership of the European Molecular Biology Organization and Fellowship of the Academy of Medical Sciences. He is Chairman of the board of Ossianix Inc and is also a member of the board of Avacta Group plc, ReNeuron Group plc, Sareum Holdoings plc, Iksuda Therapeutics and GammaDelta Therapeutics. He is also an adviser to the CRT Pioneer Fund. He holds Doctorate in Philosophy degree in Biochemistry (Amino and Acid Transport in Trypanosomes) from Cambridge University and Bachelor of Arts degree in Biochemistry from Keble College, Oxford University.